With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

The drugmaker shared limited early results from a Metsera obesity treatment as investors weigh its $10 billion acquisition and declining Covid sales.

PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength ...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...